Company profile

ImmuneOnco Biopharmaceuticals

China clinical-stage biopharma, immuno-oncology + newer PAH program

1541 · HKEX · China

Public Market Listing

1541HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for ImmuneOnco Biopharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
IMM2510
Phase 2
PD-L1 / VEGFSmall molecule
Non-Small Cell Lung Cancer
ImmuneOnco anti-PAH candidate (IMC-003)
Phase 2
Activin receptor type IIA (ActRIIA)Biologic — subtype unspecified
Hypertension

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.